Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02316353 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema
A Phase 3 study of Hereditary Angioedema Types I and II, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 3
- Development phase
- 126
- Enrollment target
- 20
- Study locations
NCT02316353 is a Phase 3 study of Hereditary Angioedema Types I and II that has completed, run by CSL Behring. The registered enrollment target is 126 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT02316353, a Phase 3 study of Hereditary Angioedema Types I and II, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 126 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of this study is to assess the long-term safety of C1-esterase inhibitor (C1-INH) in preventing hereditary angioedema (HAE) attacks when it is administered under the skin of subjects with HAE. The safety of participating subjects will be assessed for up to 54 weeks. The long-term efficacy of C1-INH will also be assessed. Each eligible subject will enter the treatment phase, wherein subjects will be randomized to treatment with either low- or medium-volume C1-INH. Subjects who have an insufficient treatment response during the study will be given an opportunity to undergo a dose increase. The study aims to enroll eligible subjects who completed study CSL830\_3001 (NCT01912456). Subjects who did not participate in study CSL830\_3001 may also participate, if eligible and if space permits. Subjects from the United States (US) who complete Treatment Period 2 will be allowed to participate in an Extension Period. During the Extension Period participating US subjects will continue to receive treatment with open-label CSL830 for up to an additional 88 weeks.
Conditions Studied
Interventions
- BIOLOGICAL C1-esterase inhibitor
Study Locations (20)
California
- Study Site - La Jolla
- Study Site - Orange
- Study Site - Walnut Creek
Ontario
- Study Site - Hamilton
- Study Site - Ottawa
- Study Site - Toronto
Other
- Study Site - Québec
- Study Site - Pilsen
- Study Site - Berlin
Alabama
- Study Site - Birmingham
Arizona
- Study Site - Scottsdale
Maryland
- Study Site - Chevy Chase
Ohio
- Study Site - Cincinnati
Oklahoma
- Study Site - Tulsa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2014-12-31 |
| Est. Completion | 2017-09-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02316353
The ClinicalTrials.gov registry entry for NCT02316353 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hereditary Angioedema Types I and II appearing as the primary indexed condition, and to 1 intervention - of which C1-esterase inhibitor is the first listed.
NCT02316353 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Ontario, Other.
Frequently Asked Questions
What is clinical trial NCT02316353 about?
NCT02316353 is a clinical study titled "A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema". The aim of this study is to assess the long-term safety of C1-esterase inhibitor (C1-INH) in preventing hereditary angioedema (HAE) attacks when it is administered under the skin of subjects with HAE. The safety of participating subjects will be assessed for up to 54 weeks. The long-term efficacy of...
What is the current status of trial NCT02316353?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 126 participants. The study started on 2014-12-31. Estimated completion is 2017-09-21.
What conditions does trial NCT02316353 study?
This clinical trial studies the following conditions: Hereditary Angioedema Types I and II.
What interventions are being tested in trial NCT02316353?
The interventions under investigation include: C1-esterase inhibitor (BIOLOGICAL).
Who is sponsoring clinical trial NCT02316353?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02316353 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Angioedema Types I and II
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.